January 16, 2019


President Abdelaziz Bouteflika Signs Five Presidential Decrees

The President of the Republic Mr. Abdelaziz Bouteflika signed five presidential decrees including ratification of cooperation agreements and memoranda of understanding concluded by Algeria with a number of countries, in accordance with Article 19.9 of the Constitution.
According to a statement issued by the Presidency of the Republic on Tuesday, the decrees are related to the “agreement to amend and extend the cooperation agreement in the field of science and technology between the Government of the People’s"...

Continue Reading >

January 16, 2019


Teradata Appoints Oliver Ratzesberger President and CEO

Teradata (NYSE: TDC), the industry’s only pervasive data intelligence company, today announced that its Board of Directors has appointed Oliver Ratzesberger President and Chief Executive Officer (CEO), effective immediately. Ratzesberger succeeds Victor L. Lund, who is transitioning from his role as President and CEO to Executive Chairman of the Board of Directors. Ratzesberger has served as Teradata’s Chief Operating Officer (COO) since February 2018, responsible for the Company’s global operations and leading its strategies for go-to-market, products and services. He joined Teradata in 2013 and, from 2016 to 2018, served as the Company’s Executive Vice President and Chief Product Officer, leading Teradata’s research and development organization, following a distinguished career in advancing innovation in technology at both established and start-up companies. While COO, Ratzesberger worked alongside Lund in architecting and implementing the Company’s transformation. This appointment reflects the Board’s confidence in Ratzesberger......

Continue Reading >

January 16, 2019


NuScale and JAEC Agree to Explore SMR Deployment in Jordan

Today, NuScale Power announced that it has signed a memorandum of understanding (MOU) with the Jordan Atomic Energy Commission (JAEC), to evaluate NuScale’s small module reactor (SMR) nuclear power plant for use in Jordan. The agreement continues to showcase the immense international interest in NuScale’s innovative nuclear technology.

JAEC is the government entity leading the development and implementation of nuclear strategy and managing"...

Continue Reading >

January 14, 2019


Algerian Politician Warns Against Unprecedented Crisis in Algeria

Rabat –Abderrazak Makri, the leader of Algerian Islamist political party, the Movement of Society for Peace (MSP) warned against an unprecedented crisis that Algeria may experience beginning in late 2019.

Starting from late 2019 until 2022, “we will experience unprecedented lean years. They will be difficult for Algeria and the ordinary citizen will feel the burden more than others,” Makri wrote on his Facebook page on January"...

Continue Reading >

January 7, 2019


Government grants Algold Resources one year extension to complete Tijirit feasibility study

Algold Resources Limited has announced that the Mauritanian Ministry of Oil, Energy and Mines has granted a 12-month extension to the Corporation for the completion of the Tijirit Gold Project feasibility study.

At Algold’s request, the Government of Mauritania granted an extension for the delivery of the feasibility study. This will allow the Corporation to pursue more technical work, including drilling, metallurgy and hydrogeology, which"...

Continue Reading >

January 4, 2019


Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna

Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna. The collaboration, established in October 2017, aims to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases, with an initial focus on nonalcoholic steatohepatitis (NASH), a devastating disease for which there is no approved treatment. The option is the second target under the two companies’ research collaboration and license agreement. Under the terms of the agreement, Boehringer Ingelheim will be responsible for future clinical development and commercialization of the therapeutic target. Dicerna is eligible to receive development and commercial milestone payments, and royalties on worldwide net sales. “It is extremely gratifying for Boehringer Ingelheim to exercise......

Continue Reading >

Forex News Headline

Forex Market Video